CA2796034A1 - Nmn modulator - Google Patents

Nmn modulator Download PDF

Info

Publication number
CA2796034A1
CA2796034A1 CA2796034A CA2796034A CA2796034A1 CA 2796034 A1 CA2796034 A1 CA 2796034A1 CA 2796034 A CA2796034 A CA 2796034A CA 2796034 A CA2796034 A CA 2796034A CA 2796034 A1 CA2796034 A1 CA 2796034A1
Authority
CA
Canada
Prior art keywords
nmn
modulator
degeneration
biomarker
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2796034A
Other languages
English (en)
French (fr)
Inventor
Michael Coleman
Laura Conforti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Babraham Institute
Original Assignee
The Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Babraham Institute filed Critical The Babraham Institute
Publication of CA2796034A1 publication Critical patent/CA2796034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2796034A 2010-04-27 2011-04-19 Nmn modulator Abandoned CA2796034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1006961.5A GB201006961D0 (en) 2010-04-27 2010-04-27 NMN modulator
GB1006961.5 2010-04-27
PCT/GB2011/050770 WO2011135332A2 (en) 2010-04-27 2011-04-19 Nmn modulator

Publications (1)

Publication Number Publication Date
CA2796034A1 true CA2796034A1 (en) 2011-11-03

Family

ID=42270852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2796034A Abandoned CA2796034A1 (en) 2010-04-27 2011-04-19 Nmn modulator

Country Status (7)

Country Link
US (1) US20130131111A1 (enExample)
EP (1) EP2563363A2 (enExample)
JP (1) JP2013525416A (enExample)
AU (1) AU2011247078A1 (enExample)
CA (1) CA2796034A1 (enExample)
GB (1) GB201006961D0 (enExample)
WO (1) WO2011135332A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328526A1 (en) * 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CN103961691A (zh) * 2013-02-03 2014-08-06 复旦大学 尼克酰胺磷酸核糖转移酶在制备神经保护药物中的用途
CN104758307A (zh) * 2015-03-16 2015-07-08 邦泰生物工程(深圳)有限公司 Nadh和nmn在制备帕金森病药物或保健品的应用
CA3123215C (en) * 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US20220160688A1 (en) * 2019-03-20 2022-05-26 The Johns Hopkins University Inhibition of nampt and/or sarm1 for the treatment of axonal degradation
JP2020156463A (ja) * 2019-03-20 2020-10-01 株式会社リコー インビトロで細胞を評価する方法、細胞基板、及び細胞基板の製造方法
EP3712253A1 (en) * 2019-03-20 2020-09-23 Ricoh Company, Ltd. Method of in vitro cellular assay, cell circuit board, and method of manufacturing cell circuit board
CN115605207A (zh) * 2020-05-14 2023-01-13 葡默药物技术有限公司（Us） 用于经粘膜给药的固体剂型
CN112569289A (zh) * 2020-12-24 2021-03-30 深圳市旷逸生物科技有限公司 一种含有nmn的帕金森治疗药物及其制备方法
US12364681B2 (en) 2021-01-08 2025-07-22 The Johns Hopkins University Combined MAPK and NAMPT inhibition for treatment of neuron degeneration
CN117582405A (zh) * 2023-11-21 2024-02-23 广东药科大学 一种烟酰胺单核苷酸纳米复乳及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797478B1 (en) * 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
CA2462632A1 (en) * 2001-10-01 2003-04-10 Emory University Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases
WO2003082187A2 (en) * 2002-03-26 2003-10-09 Indiana University Purification and cloning of nmn adenylyltranserase and its therapeutic use
WO2004035823A2 (en) * 2002-10-17 2004-04-29 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
WO2008026018A1 (en) * 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2098231A1 (en) * 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CN102186822A (zh) * 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
GB0902147D0 (en) * 2009-02-10 2009-03-25 Babraham Inst NMNAT2 modulator

Also Published As

Publication number Publication date
AU2011247078A1 (en) 2012-11-08
EP2563363A2 (en) 2013-03-06
US20130131111A1 (en) 2013-05-23
WO2011135332A4 (en) 2012-02-23
WO2011135332A3 (en) 2011-12-22
JP2013525416A (ja) 2013-06-20
WO2011135332A2 (en) 2011-11-03
GB201006961D0 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
US20130131111A1 (en) Nmn modulators for the treatment of neurodegenerative disorders
Xie et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration
JP6994469B2 (ja) Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法
Shan et al. Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia
US20160008380A1 (en) Targeting glutamine metabolism in brain tumors
EP2478375B1 (en) Diagnostic agent for parkinson's disease
WO2003032894A2 (en) Method of monitoring neuroprotective treatment
US20260130908A1 (en) Methods and compounds modifying mitochondrial function
Paré et al. The development of a targeted and more potent, anti-Inflammatory derivative of colchicine: Implications for gout
Liao et al. Application of immobilized ATP to the study of NLRP inflammasomes
JP2011523710A (ja) ヒートショック応答調節因子のスクリーニング方法
JPWO2019198825A1 (ja) 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬
Gao et al. Inhibition of α-synuclein aggregation by MCC950 attenuates dopaminergic neuronal damage in MN9D cells
Yu et al. An ALS assembly modulator signature in peripheral blood mononuclear cells: implications for ALS pathophysiology, therapeutics, and diagnostics
EP4084827A1 (en) Kinases as biomarkers for neurodegenerative conditions
EP2529230A2 (en) Biomarkers
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
US20180136216A1 (en) Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus
WO2010092317A1 (en) Nmnat2 modulator
Yin et al. PARL stabilizes mitochondrial BCL-2 via Nur77-mediated scaffolding as a therapeutic strategy for Parkinson’s disease
JP6290398B2 (ja) 多発性硬化症（ｍｓ）を監視する方法および予測キット
Baybutt et al. The proliferative effects of retinoic acid on primary cultures of adult rat type II pneumocytes depend upon cell density
TW202406543A (zh) Pde4抑制劑臨床反應之預測性生物標記
KR20260071734A (ko) 천식에서 생물학적 제제의 치료반응성 예측을 위한 대사체 바이오마커
CN118511076A (zh) 新分析方法和治疗哈钦森-吉尔福德早衰综合征的新方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160420